Marc Ullman  will be a speaker at the Dietary Supplement Good Manufacturing Practices (GMP) Compliance Seminar, with a special section on applying GMP concepts to the cannabis industry. The program will take place at Hotel Indigo in Dallas, Texas in September 2018.

At the Dietary Supplement GMP Seminar, You Will:

• Receive detailed practical guidance

Marc Ullman was quoted in a NutraIngredients-USA article, “FDA says Gottlieb statement does not signal CBD enforcement shift, but some questions unanswered, observers say.”

A statement by FDA Commissioner Dr. Scott Gottlieb noted that the US Food and Drug Administration has approved the first CBD drug, which was developed by English company GW Pharmaceuticals. The

Marc Ullman was quoted in a Natural Products Insider article entitled, “FDA Triggered Industry Shift from ‘CBD’ to ‘Hemp Extracts’ in Dietary Supplements.” The article addresses the point that amid the escalating demands for CBD in the United States, many companies are selling “hemp extracts,” a strategy based on regulatory and scientific considerations.”

“If you’re

Marc Ullman was interviewed for an article in Natural Products Insider entitled, “Hemp Lawyer: FDA CBD Warning Letters Shouldn’t Alarm Industry.” The article centers on the FDA’s intolerance of claims that CBD-containing foods and dietary supplements treat diseases such as cancer. The FDA advised that  CBD (cannabidiol) cannot be sold in dietary supplements, or added to

Marc Ullman was quoted in a recent Nutritional Outlook article entitled, “Will Hemp CBD’s Regulatory Controversy Help or Hurt Its Future as a Supplement Ingredient?”

To read the full article, Click Here.